Kidney cancer news
Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours
Just over half of the patients from a phase 2 [...]
Quality of life on lenvatinib plus pembrolizumab combination
In this study, the health-related quality of life (HRQoL) of [...]
Transforming lives, raising productivity
The Association of the British Pharmaceutical Industry (ABPI) has commissioned [...]
Tougher cancer diagnostic target as part of government’s ‘war on cancer’
The following was published in the Health Service Journal (HSJ) [...]
Breakthrough COVID-19 infections in vaccinated cancer patients
This study used real world data from the National COVID [...]
MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer
MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]
Most used Tags
renal cell carcinoma immunotherapy checkpoint inhibitors combination therapy Cancer TKIs overall survival nivolumab Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx COVID-19 cancer survival ipilimumab VEGF inhibitors axitinib Inlyta pembrolizumab coronavirus non-clear cell kidney cancer Yervoy Keytruda risk factors biological markers metastases targeted therapy papillary RCC everolimus Afinitor ASCO adjuvant therapy first-line treatment cancer outcomes NICE partial nephrectomyArchives
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
